Sumitomo Pharma America, Inc.
- Country
- πΊπΈUnited States
- Ownership
- Subsidiary
- Established
- 1984-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.sunovion.com
A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer
- Conditions
- Cancer
- Interventions
- First Posted Date
- 2015-06-26
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 165
- Registration Number
- NCT02483247
- Locations
- πΊπΈ
Indiana University Health Goshen, Goshen, Indiana, United States
πΊπΈLouisiana State Univesity, New Orleans, Louisiana, United States
π¨π¦Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease
- First Posted Date
- 2015-06-11
- Last Posted Date
- 2020-07-30
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 141
- Registration Number
- NCT02469090
- Locations
- π¨π¦
UHN Toronto Western Hospital, Toronto, Ontario, Canada
πΊπΈEmory University Department of Neurology, Atlanta, Georgia, United States
πΊπΈThe Research Center of Southern California, Oceanside, California, United States
A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers
- Conditions
- Cancer
- Interventions
- First Posted Date
- 2015-06-10
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT02467361
- Locations
- πΊπΈ
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
πΊπΈEmory University Winship Cancer Institute, Atlanta, Georgia, United States
πΊπΈUniversity of Colorado Cancer Center, Denver, Colorado, United States
Dasotraline Pediatric Extension Study
- First Posted Date
- 2015-05-29
- Last Posted Date
- 2020-01-28
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 237
- Registration Number
- NCT02457819
- Locations
- πΊπΈ
Psychiatric Associates, Overland Park, Kansas, United States
πΊπΈHarmonex Neuroscience Research, Inc, Dothan, Alabama, United States
πΊπΈClinical Trials group at the Rochester Center for Behavioral Medicine, Rochester Hills, Michigan, United States
A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation
- First Posted Date
- 2015-05-04
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT02432690
- Locations
- πΊπΈ
Mayo Clinic, Rochester, Minnesota, United States
A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors
- First Posted Date
- 2015-05-04
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 147
- Registration Number
- NCT02432326
- Locations
- πΊπΈ
Weill Cornell Medical College, New York, New York, United States
πΊπΈTexas Oncology - Tyler, Tyler, Texas, United States
πΊπΈNorthwest Cancer Specialists, PC, Vancouver, Washington, United States
Dasotraline Pediatric ADHD Study
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Drug: Placebo Comparator
- First Posted Date
- 2015-04-28
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 330
- Registration Number
- NCT02428088
- Locations
- πΊπΈ
Gulfcoast Clinical Research, Fort Myers, Florida, United States
πΊπΈNeurobehaviorial Medicine Group, PLLC, Bloomfield Hills, Michigan, United States
πΊπΈHarmonex Neuroscience Research, Dothan, Alabama, United States
A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies
- Conditions
- Hematologic Malignancy
- Interventions
- First Posted Date
- 2015-02-02
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT02352558
- Locations
- πΊπΈ
Virginia Oncology Associates, Norfolk, Virginia, United States
πΊπΈWest Clinic, Germantown, Tennessee, United States
πΊπΈNorthwest Cancer Specialists, PC, Vancouver, Washington, United States
A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma
- First Posted Date
- 2014-12-12
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT02315534
- Locations
- πΊπΈ
Laura and Isaac Perlmutter Cancer Center, New York, New York, United States
π¨π¦University of Calgary, Calgary, Alberta, Canada
π¨π¦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2014-10-31
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 97
- Registration Number
- NCT02279719
- Locations
- πΊπΈ
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
πΊπΈTexas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
πΊπΈPiedmont Cancer Institute, P.C., Atlanta, Georgia, United States